About one in three people with major depressive disorder do not get adequate relief from antidepressants, even after trying multiple medications at appropriate doses and for appropriate durations. For most of those patients, the clinical explanation they receive is that they need to keep trying different options in the same class. The research tells a different story.
What Treatment-Resistant Depression Actually Means
Treatment-resistant depression (TRD) is a clinical designation for a major depressive episode that has not responded adequately to at least two antidepressant medications taken at therapeutic doses and for a sufficient duration, typically six to eight weeks per trial. The designation is not a prognosis and it is not a statement about a patient’s character or resilience. It is a clinical signal that the specific biological mechanisms driving their depression may not be the ones that standard medications are designed to address.
At Valor Health Solutions, most patients who come to us for ketamine infusion therapy have a documented history of multiple antidepressant trials. Many have been in and out of treatment for years. The common thread is not that they failed treatment. It is that the treatments available to them targeted a specific set of pathways, and those pathways may not be the primary drivers of their depression.
How Standard Antidepressants Work
First-line antidepressants, primarily selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), work by increasing the availability of serotonin, norepinephrine, or both in the brain’s synaptic pathways. For a significant portion of people with depression, this produces meaningful improvement. These medications are well-studied, generally well-tolerated, and clinically appropriate as a first approach.
The limitation is that depression is not a single-pathway condition. Serotonin and norepinephrine are two of several neurotransmitter systems involved in mood regulation. For patients whose depression is driven primarily by disruptions in other systems, medications that target only serotonin and norepinephrine may produce little to no effect regardless of dose or duration. Changing from one SSRI to a different SSRI does not address that underlying issue.
The Glutamate System and NMDA Receptors
Glutamate is the brain’s primary excitatory neurotransmitter. It is involved in synaptic plasticity, which is the ability of brain cells to form and strengthen connections over time, and it plays a central role in mood regulation, learning, and memory. Research has established the glutamate system as a key pathway in the neurobiology of treatment-resistant depression, and specifically that disruptions in glutamate signaling may underlie cases where serotonin-targeted treatment has failed (National Institutes of Health).
Ketamine acts on this system by blocking a class of glutamate receptors called NMDA receptors. This mechanism is distinct from every major class of conventional antidepressant. Rather than gradually adjusting the availability of serotonin or norepinephrine over weeks, ketamine produces rapid modulation of glutamate signaling, which clinical research has shown can generate significant antidepressant effects within hours in patients who have not responded to prior medications (National Institutes of Health).
The National Institute of Mental Health highlighted research in 2024 supporting ketamine as a rapid-acting treatment option offering genuine clinical hope for patients who have exhausted standard care (National Institute of Mental Health, 2024). Ketamine is not experimental for TRD. It is an evidence-backed option for a population that previously had few alternatives.
What This Means in Practice
The practical implication for patients with treatment-resistant depression is that switching from one SSRI to another, or adding a second medication in the same class, is unlikely to resolve the problem if the underlying mechanism involves glutamate rather than serotonin. Ketamine works on a different system entirely, which is why it can produce a response in patients who have failed multiple prior trials.
At Valor Health Solutions, we offer IV ketamine infusions as our primary treatment for TRD. The standard course is six infusions spread over two to three weeks, administered in a private clinical setting with a licensed provider present throughout each session. Our 40-minute infusion sessions start at $360. For patients who respond well and want an ongoing maintenance option, we also offer a one-month oral ketamine program as a step-down or bridging treatment between infusion series.
We do not present ketamine as a guaranteed solution. Results vary by individual, and not every patient with TRD will respond. What we offer is a clinically grounded evaluation that determines whether ketamine is an appropriate next step for your specific history, and a treatment structure designed to give it the best possible chance to work. We encourage every patient to discuss these options thoroughly with their provider before making any decisions.
A Word on Cost and Uncertainty
The two most common barriers patients with TRD raise before starting ketamine are cost and the very reasonable fear that it will not work after so much else has not. Both concerns deserve a direct response.
On cost: a full six-session course at our starting rate begins at $2,160. Most IV ketamine is self-pay, though we accept HSA and FSA cards and offer CareCredit financing with promotional periods of 6, 12, 18, or 24 months. Veterans who qualify through the VA Community Care program may receive IV ketamine and psychotherapy at no cost. We walk through all financial options with every patient before any treatment is scheduled.
On uncertainty: we do not promise outcomes we cannot guarantee. What we can say is that ketamine acts through a mechanism that is genuinely different from every treatment most TRD patients have previously tried. For a meaningful subset of that population, that difference is clinically significant.
Frequently Asked Questions
If I’ve tried many antidepressants and none worked, why would ketamine be different?
Because it targets a different system. Most antidepressants work on serotonin or norepinephrine pathways. Ketamine works on the glutamate system through NMDA receptor blockade, a mechanism distinct from every major antidepressant class. For patients whose depression involves glutamate dysregulation rather than serotonin disruption, this represents a genuinely different pharmacological approach. It is not a guarantee, but it is a legitimate reason to consider it when the standard options have not worked.
Does ketamine work immediately?
Clinical research has shown ketamine can produce measurable antidepressant effects within hours of an infusion, substantially faster than standard antidepressants. The full therapeutic benefit typically develops over a six-session series rather than after a single infusion. Some patients notice a shift quickly; others see improvement build across sessions. Individual response patterns vary.
Is ketamine FDA-approved for treatment-resistant depression?
IV ketamine administered at infusion clinics is used off-label for TRD. SPRAVATO® (esketamine), a nasal spray form of ketamine that we also offer, carries FDA approval specifically for treatment-resistant depression and is administered in-clinic under the FDA’s REMS program requirements. Your provider will explain which option fits your situation during the evaluation.
Will my insurance cover ketamine for TRD?
IV ketamine infusions are typically self-pay. SPRAVATO® is often covered by insurance for qualifying patients with TRD. Our team reviews coverage with every patient before treatment begins so there are no surprises on the financial side.
Key Takeaways
- Treatment-resistant depression is defined as inadequate response to at least two antidepressants at therapeutic doses and durations. It is a clinical signal about mechanism, not a statement about prognosis.
- Standard antidepressants target serotonin and norepinephrine. For patients whose depression involves the glutamate system, these medications may produce little effect regardless of dose or duration.
- Ketamine works through NMDA receptor blockade in the glutamate system, a mechanism distinct from every major class of conventional antidepressant, and can produce effects within hours.
- The National Institute of Mental Health has identified ketamine as a rapid-acting option offering clinical hope for patients who have exhausted standard care.
- Results vary by individual. A clinical evaluation at Valor Health Solutions is the starting point for understanding whether ketamine is the right next step for your specific history.
If standard antidepressants have not worked for you, understanding why is the first useful step toward finding what might. At Valor Health Solutions, we serve patients in Clearwater, FL and Johnson City, TN who have often spent years in treatment without finding the relief they needed. A $49 consultation, applied toward your first treatment if you proceed, is where that conversation starts. Call us at 888-214-2144 or book through our patient portal.
References
- National Institutes of Health. Ketamine works by blocking NMDA receptors in the glutamate system, producing rapid antidepressant effects through a mechanism distinct from traditional antidepressants. https://pmc.ncbi.nlm.nih.gov/articles/PMC5148235/
- National Institutes of Health. Studies show ketamine produces rapid antidepressant effects in patients with treatment-resistant major depression who have not responded to other medications. https://pubmed.ncbi.nlm.nih.gov/23982301/
- National Institute of Mental Health. (2024). New hope for rapid-acting depression treatment. https://www.nimh.nih.gov/news/science-updates/2024/new-hope-for-rapid-acting-depression-treatment
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine therapy should only be pursued under the supervision of a licensed medical provider with full knowledge of your medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.
